Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-23
2010-11-02
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07825137
ABSTRACT:
The present invention relates to the use of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, a novel c-Met/HGFR inhibitor, for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer.
REFERENCES:
patent: 6313137 (2001-11-01), Amin et al.
patent: 6498165 (2002-12-01), Armstrong et al.
patent: 6825198 (2004-11-01), Chiang et al.
patent: 6992087 (2006-01-01), Verhoest et al.
patent: 6995161 (2006-02-01), Yoon et al.
patent: 7205408 (2007-04-01), Davies et al.
patent: 7230098 (2007-06-01), Cui et al.
patent: 2006/0046991 (2006-03-01), Cui et al.
patent: 2006/0128724 (2006-06-01), Cui et al.
patent: 2006/0178374 (2006-08-01), Cui et al.
patent: 2007/0072874 (2007-03-01), Cui et al.
patent: 0 204 285 (1992-01-01), None
patent: 1 044 967 (2004-08-01), None
patent: 7 109260 (1995-04-01), None
patent: WO 93/15055 (1993-08-01), None
patent: WO 98/37080 (1998-08-01), None
patent: WO 99/55706 (1999-11-01), None
patent: 2006/021884 (2006-03-01), None
Zou et al. Cancer Res., 2007, vol. 67, No. 9, pp. 4408-4417.
Aebersold, D., et al., “Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx,”Oncogene, 2003, 8519-8523, vol. 22, No. 52.
Bradbury H., et al., “New Non-Peptide Endothelin-A Receptor Antagonists: Synthesis, Biological Properties, and Structure-Activity Relationships of 5-(Dimethylamino)-N-pyridyl-, -N-pyrimidinyl-, -N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides,”Journal of Medicinal Chemistry, 1997, 996-1004, vol. 40, No. 6.
Bristol, J., et al., “An Improved Synthesis of 2-Amino-3-alkyloxypyridines by a Phase-Transfer Catalyzed Ether Synthesis,”Synthesis, 1981, 971-973, vol. 12.
Christensen, J., et al., “c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention,”Cancer Letters, 2005, 1-26, vol. 225, No. 1.
Dennin, F., et al., “Synthesis of Derivatives of Pyrazino[1,2-α]pyrimidin-4-ones,”Journal of Heterocyclic Chemistry, 1990, 1639-1643, vol. 27.
Di Renzo, M., et al, “Overexpression and Amplification of the Met/HGF Receptor Gene during the Progression of Colorectal Cancer,”Clinical Cancer Research, 1995, 147-154, vol. 1.
Di Renzo, M., et al., “Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas,”Oncogene, 2000, 1547-1555, vol. 19, No. 12.
Foks, H., et al, “Studies on Pyrazine Derivatives. XXX. Synthesis of Pyrazinylamino-1,3-Diazacycloalkanes of Potential Circulatory Activity,”Acta Poloniae Pharmaceutica, 1997, 55-62, vol. 54, No. 1.
Gallego, M., et al., “Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways,”Oncogene, 2003, 8498-8508, vol. 22.
Gavezzotti, A., “Are Crystal Structures Predictable?,”Accounts of Chemical Research, 1994, 309-314, vol. 27, No. 10.
Graveel, C., et al., “Tumorigenic Effects of Activating Met Mutations in a Knock-in Mouse Model,”Proceedings of the American Association for Cancer Research, 2004, 5102, vol. 45.
Hanahan, D., et al., “The Hallmarks of Cancer,”Cell, 2000, 57-70, vol. 100.
Hara, T., et al., “Amplification of c-myc, K-sam, and c-met in Gastric Cancers: Detection by Fluorescence in Situ Hybridization,”Laboratory Investigation, 1998, 1143-1153, vol. 78, No. 9.
Kaminski, J., et al., “Antiulcer Agents. 2. Gastric Antisecretory, Cytoprotective, and Metabolic Properties of Substituted Imidazo[ 1,2-a ]pyridines and Analogues,”Journal of Medicinal Chemistry, 1987, 2031-2046, vol. 30, No. 11.
Jeffers, M., et al., “Activating mutations for the Met tyrosine kinase receptor in human cancer,”Proceedings of the National Academy of Science of the United States of America, 1997, 11445-11450, vol. 94, No. 21.
Jeffers, M., et al., “The mutationally activated Met receptor mediates motility and metastasis,”Proceedings of the National Academy of Science of the United States of America, 1998, 14417-14422, vol. 95, No. 24.
Kuniyasu, H., et al., “Frequent Amplification of thec-metGene in Scirrhous Type Stomach Cancer,”Biochemical and Biophysical Research Communications, 1992, 227-232, vol. 189, No. 1.
Lee, J., et al., “A novel germ line juxtamembraneMetmutation in human gastric Cancer,”Oncogene, 2000, 4947-4953, vol. 19.
Lorenzato, A., et al., “Novel Somatic Mutations of theMETOncogene in Human Carcinoma Metastases Activating Cell Motility and Invasion,”Cancer Research, 2002, 7025-7030, vol. 62, No. 23.
Ma, P., et al., “c-MET Expression/Activation, Functions, and Mutations in Non-small Cell Lung Cancer,”Proceedings of the American Association for Cancer Research, 2004, 1875, vol. 45.
Ma, P., et al., “c-MetMutational Analysis in Small Cell Lung Cancer: Novel Juxtamembrane Domain Mutations Regulating Cytoskeletal Functions,”Cancer Research, 2003, 6272-6281, vol. 63, No. 19.
Otsuka, T., et al., “c-Met Autocrine Activation Induces Development of Malignant Melanoma and Acquisition of the Metastatic Phenotype,”Cancer Research, 1998, 5157-5167, vol. 58, No. 22.
Park, W., et al., “Somatic Mutations in the Kinase Domain of theMet/Hepatocyte Growth Factor Receptor Gene in Childhood Hepatocellular Carcinomas,”Cancer Research, 1999, 307-310, vol. 59, No. 2.
Pulford, K., et al., “Anaplastic Lymphoma Kinase Proteins in Growth Control and Cancer,”Journal of Cellular Physiology, 2004, 330-358, vol. 199.
Schmidt, L., et al., “Germline and somatic mutations in the tyrosine kinase domain of theMETproto-oncogene in papillary renal carcinomas,”Nature Genetics, 1997, 68-73, vol. 16, No. 1.
Schmidt, L., et al., “Novel mutations of the MET proto-oncogene in papillary renal carcinomas.”Oncogene, 1999, 2343-2350, vol. 18, No. 14.
Schmidt, L., et al., “Two North American Families with Hereditary Papillary Renal Carcinoma and Identical Novel Mutations in the MET Proto-Oncogene,”Cancer Research, 1998, 1719-1722, vol. 58, No. 8.
Shimomura, O., et al., “Semi-synthetic aequorins with improved sensitivity to Ca2+ ions,”Biochemical Journal, 1989, 913-920, vol. 261.
Sollogoub, M., et al., “First synthesis of 1-deazacytidine, theC-nucleoside analogue of Cytidine,”Tetrahedron Letters, 2002, 3121-3123, vol. 43.
Takayama, H., et al., “Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factoryscatter factor,”Proceedings of the National Academy of Science of the United States of America, 94, 701-706, vol. 94, No. 2.
Vippagunta, S., et al., “Crystalline Solids,”Advanced Drug Delivery Reviews, 2001, 3-26, vol. 48.
Wan, W., et al., “Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells,”Blood, 2006, 1617-1623, vol. 107, No. 4.
Christensen James Gail
Zou Yahong
Anderson James D
Liptak Vincent P.
Pfizer Inc.
Prodnuk Stephen D.
Tidwell Jeffrey H.
LandOfFree
Method of treating abnormal cell growth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating abnormal cell growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating abnormal cell growth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4167348